how big is Hemo Organic?

As of Jun 06, Hemo Organic Ltd has a market capitalization of 4.00 Cr, with recent net sales of 2.41 Cr and a net profit of 0.16 Cr. The latest balance sheet shows shareholder's funds of -0.32 Cr and total assets of 0.92 Cr.

Market Cap: As of Jun 06, Hemo Organic Ltd has a market capitalization of 4.00 Cr, classifying it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest 4 quarters, Hemo Organic reported Net Sales of 2.41 Cr and a Net Profit of 0.16 Cr. This data is based on Standalone financials.<BR><BR>Balance Sheet Snapshot: The Standalone balance sheet for the latest annual period ending in Mar'24 shows Shareholder's Funds of -0.32 Cr and Total Assets of 0.92 Cr.

Who are in the management team of Hemo Organic?

As of March 2021, the management team of Hemo Organic includes Dineshbhai S Patel (Chairman & Managing Director), Sonal D Patel (Executive Director), Krushanakant R Patel (Independent Director), Sanjeev Lodha (Additional Independent Director), Siyona Jhnawar (Director), and Nishita Mayank Sanghvi (Company Secretary).

As of March 2021, the management team of Hemo Organic includes the following members:<BR><BR>1. Dineshbhai S Patel - Chairman & Managing Director<BR>2. Sonal D Patel - Executive Director<BR>3. Krushanakant R Patel - Independent Director<BR>4. Sanjeev Lodha - Additional Independent Director<BR>5. Siyona Jhnawar - Director<BR>6. Nishita Mayank Sanghvi - Company Secretary<BR><BR>These individuals play key roles in the governance and management of the company.

What does Hemo Organic do?

Hemo Organic Ltd produces and sells white coal, ayurvedic medicines, and chemicals, classified as a Micro Cap company. As of March 2025, it reported net sales of 2 Cr and a market cap of Rs 4 Cr.

Overview:<BR>Hemo Organic Ltd is engaged in the production and sale of white coal, ayurvedic medicines, and chemicals within the Trading & Distributors industry, classified as a Micro Cap company.<BR><BR>History:<BR>Incorporated in August 1992, Hemo Organic Ltd was formerly known as Dinesh Allorga Limited. The company initially focused on manufacturing chemicals but discontinued this due to a pollution crisis. The latest quarterly results reported net sales and profit for March 2025.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 2 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 4 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 4.00 <BR>Industry P/E: 32 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.47 <BR>Return on Equity: -16.00% <BR>Price to Book: -3.73 <BR><BR>Contact Details:<BR>Address: 8-A Gulnar Chinar-Gulnar Apart, V V Nagar Road Anand Gujarat : 388001 <BR>Tel: 91-2692-248535 <BR>Email: drdineshpatel@rediffmail.com <BR>Website: http://www.hemoorganic.com

Has Hemo Organic declared dividend?

No Dividend History Available

Who are the peers of the Hemo Organic?

Hemo Organic's peers include Redington, MMTC, MSTC, Ravindra Energy, Saptak Chem &, and Chambal Brewer. Redington shows excellent management and growth, while Ravindra Energy has the highest 1-year return at 141.63%, and Hemo Organic's return is -4.95%.

Peers: The peers of Hemo Organic are Redington, MMTC, MSTC, Ravindra Energy, Saptak Chem &, and Chambal Brewer.<BR><BR>Quality Snapshot: Excellent management risk is observed at Redington, while Average management risk is found at MMTC and MSTC, and the rest have Below Average or do not qualify. Growth is Excellent at Redington, Below Average at MMTC and MSTC, while Ravindra Energy has Below Average growth, and Saptak Chem & does not qualify. In terms of Capital Structure, Excellent is noted at MSTC, Good at Redington, and the rest have Below Average or do not qualify.<BR><BR>Return Snapshot: Ravindra Energy has the highest 1-year return at 141.63%, while MSTC has the lowest at -39.89%. Hemo Organic's 1-year return is -4.95%, which is higher than MSTC's but lower than Ravindra Energy's. Additionally, MSTC and Chambal Brewer have negative six-month returns.

Is Hemo Organic overvalued or undervalued?

As of April 1, 2024, Hemo Organic's valuation has shifted to risky due to overvaluation indicated by a PE ratio of 3.75 and poor performance compared to peers, with its stock declining 83.96% over the past three years versus a 49.13% increase in the Sensex.

As of 1 April 2024, Hemo Organic's valuation grade has moved from does not qualify to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued based on its current metrics, with a PE ratio of 3.75, an EV to EBIT of -5.22, and a PEG ratio of 0.02, all of which suggest significant financial distress and poor profitability.<BR><BR>In comparison to its peers, Hemo Organic's valuation stands out negatively against companies like Altius Telecom, which has a PE ratio of 52.97 and is rated very attractive, and Sagility India, which is rated fair with a PE of 33.73. The stark contrast in these ratios highlights Hemo Organic's struggles within the trading and distribution industry. Additionally, the company's stock performance has lagged behind the Sensex, particularly over the past three years, where it has declined by 83.96% compared to a 49.13% increase in the index.

What is the technical trend for Hemo Organic?

As of June 2, 2025, Hemo Organic's trend is sideways with mixed signals: while the weekly and monthly MACD and Bollinger Bands show mild bullishness, daily moving averages indicate short-term weakness, resulting in overall market indecision.

As of 2 June 2025, the technical trend for Hemo Organic has changed from mildly bullish to sideways. The weekly MACD remains mildly bullish, while the monthly MACD is also mildly bullish, indicating some positive momentum. However, the daily moving averages are mildly bearish, suggesting short-term weakness. The Bollinger Bands are bullish on both weekly and monthly time frames, which supports the overall bullish sentiment. The KST shows a mixed picture with weekly mildly bullish and monthly mildly bearish readings. Both the Dow Theory and RSI indicate no clear trend. Overall, the current stance is neutral with mixed signals, reflecting indecision in the market.

Who are the top shareholders of the Hemo Organic?

The top shareholders of Hemo Organic include Dineshbhai Shanabhai Patel with 15.49%, and the Indian Clearing Corporation Limited at 8.08%. Individual investors collectively own 71.11% of the shares, with no institutional holdings or pledged promoter shares reported.

The top shareholders of Hemo Organic include Dineshbhai Shanabhai Patel, who holds the largest stake at 15.49%. The highest public shareholder is the Indian Clearing Corporation Limited, with an ownership of 8.08%. Additionally, individual investors collectively hold a significant portion of the company, accounting for 71.11% of the shares. There are no institutional holdings or pledged promoter shares reported.

Are Hemo Organic latest results good or bad?

Hemo Organic's latest results show a mixed performance: while it reported a profit of Rs 0.28 crore, a turnaround from last year's loss, net sales dropped by 100% and standalone net profit decreased by 124.32%. Overall, the results are concerning, reflected by a decline in performance score and a 'Strong Sell' rating from MarketsMOJO.

Hemo Organic's latest results present a mixed picture. On one hand, the company has shown improvement in its Profit After Tax (PAT), reporting Rs 0.28 crore for the latest six-month period, which is a significant turnaround from the previous year's loss of Rs -0.44 crore. This indicates a positive shift in profitability.<BR><BR>However, the overall financial performance for the quarter ending June 2025 has been flat, with a decline in key metrics. Net sales saw a dramatic drop of 100%, and the standalone net profit decreased by 124.32% compared to the previous quarter. Additionally, the company's performance score has declined from 7 to 3 over the past three months, and it has received a 'Strong Sell' rating from MarketsMOJO, reflecting concerns about its market position.<BR><BR>In summary, while there are positive signs in profitability, the significant declines in sales and profit metrics suggest that the overall results are not favorable. Stakeholders will need to keep a close eye on the company's performance in the upcoming quarters.

When is the next results date for Hemo Organic?

The next results date for Hemo Organic is 14 November 2025.

The next results date for Hemo Organic is scheduled for 14 November 2025.

How has been the historical performance of Hemo Organic?

Hemo Organic has shown significant financial improvement, with net sales rising to 2.41 Cr in March 2025 from 0.02 Cr in March 2024, and profit after tax increasing to 0.16 Cr, a recovery from a loss of 0.26 Cr the previous year. Despite rising expenditures, the company achieved positive operating profit and improved earnings per share to 0.46.

Answer:<BR>The historical performance of Hemo Organic shows a significant increase in net sales, reaching 2.41 Cr in March 2025, up from just 0.02 Cr in March 2024 and 0.00 Cr in March 2023. Total operating income also rose sharply to 2.41 Cr in March 2025, compared to 0.02 Cr in the previous year. However, the company has faced challenges with total expenditure, which increased to 2.46 Cr in March 2025 from 0.27 Cr in March 2024. This led to an operating profit (PBDIT) of 0.02 Cr in March 2025, a recovery from a loss of 0.25 Cr in March 2024. Profit before tax improved to 0.03 Cr in March 2025, while profit after tax reached 0.16 Cr, a notable turnaround from a loss of 0.26 Cr in March 2024. The earnings per share also reflected this positive trend, increasing to 0.46 in March 2025 from -0.75 in March 2024.<BR><BR>Breakdown:<BR>Hemo Organic's financial trajectory has shown marked improvement, particularly in net sales and profitability. The company reported net sales of 2.41 Cr in March 2025, a substantial increase from previous years, indicating a strong growth trend. Despite rising total expenditures, which reached 2.46 Cr, the operating profit turned positive at 0.02 Cr, contrasting sharply with the losses recorded in earlier years. The profit before tax also saw a positive shift to 0.03 Cr, and profit after tax surged to 0.16 Cr, showcasing a significant recovery from prior losses. The earnings per share improved to 0.46, reflecting the company's enhanced financial health. Overall, while Hemo Organic has faced challenges, the latest results indicate a promising turnaround in its financial performance.

Should I buy, sell or hold Hemo Organic?

Which are the latest news on Hemo Organic?

Why is Hemo Organic falling/rising?

As of 03-Dec, Hemo Organic Ltd's stock price is rising to 13.19, reflecting a 4.93% increase. This surge is driven by a strong performance over the past week and month, despite a decline in investor participation.

As of 03-Dec, Hemo Organic Ltd's stock price is rising, currently at 13.19, reflecting a change of 0.62 (4.93%) upward. This increase can be attributed to several factors. Over the past week, the stock has shown a remarkable performance, gaining 27.19%, while the benchmark Sensex has decreased by 0.59%. Additionally, in the last month, Hemo Organic's stock has risen by 57.02%, significantly outperforming the Sensex, which only increased by 1.34%.<BR><BR>The stock has been on a positive trend, with consecutive gains for the last five days, contributing to its overall rise. It is also trading above its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating strong momentum. However, it is worth noting that there has been a decline in investor participation, with delivery volume dropping by 37.41% compared to the 5-day average. Despite this decrease in participation, the stock remains liquid enough for trading.<BR><BR>Overall, the combination of strong recent performance, consistent gains, and favorable trading conditions has led to the rise in Hemo Organic's stock price.